EZH2 inhibitors in immunotherapy of melanoma

被引：1
|
作者：
Hersey, Peter
Gallagher, Stuart
Tiffen, Jessamy
Shklovskaya, Elena
Wilson, Stephen
Filipp, Fabian
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
基金：
美国国家卫生研究院; 澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
10.1158/1538-7445.AM2017-1676
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1676
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Covalent inhibitors of EZH2: Design, synthesis and evaluation
    Zhang, Qiangsheng
    Chen, Xinyi
    Hu, Xi
    Duan, Xianjie
    Wan, Guoquan
    Li, Lu
    Feng, Qiang
    Zhang, Yiqian
    Wang, Ningyu
    Yu, Luoting
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 147
  • [22] SAH derived potent and selective EZH2 inhibitors
    Kung, Pei-Pei
    Huang, Buwen
    Zehnder, Luke
    Tatlock, John
    Bingham, Patrick
    Krivacic, Cody
    Gajiwala, Ketan
    Diehl, Wade
    Yu, Xiu
    Maegley, Karen A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1532 - 1537
  • [23] Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
    Lanzi, Cinzia
    Arrighetti, Noemi
    Pasquali, Sandro
    Cassinelli, Giuliana
    BIOCHEMICAL PHARMACOLOGY, 2023, 215
  • [24] The epigenetic modifier EZH2 represses antitumor immunity in melanoma
    Tiffen, Jessamy
    Shklovskaya, Elena
    Gallagher, Stuart
    Gunatilake, Dilini
    Hersey, Peter
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Verification of EZH2 as a druggable target in metastatic uveal melanoma
    Bei Jin
    Ping Zhang
    Hailin Zou
    Huijing Ye
    Yun Wang
    Jing Zhang
    Huasheng Yang
    Jingxuan Pan
    Molecular Cancer, 19
  • [26] Expression of polycomb group protein EZH2 in nevi and melanoma
    McHugh, Jonathan B.
    Fullen, Douglas R.
    Ma, Linglei
    Kleer, Celina G.
    Su, Lyndon D.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2007, 34 (08) : 597 - 600
  • [27] Verification of EZH2 as a druggable target in metastatic uveal melanoma
    Jin, Bei
    Zhang, Ping
    Zou, Hailin
    Ye, Huijing
    Wang, Yun
    Zhang, Jing
    Yang, Huasheng
    Pan, Jingxuan
    MOLECULAR CANCER, 2020, 19 (01)
  • [28] Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
    Mahmoud, Fade
    Shields, Bradley
    Makhoul, Issam
    Hutchins, Laura F.
    Shalin, Sara C.
    Tackett, Alan J.
    CANCER BIOLOGY & THERAPY, 2016, 17 (06) : 579 - 591
  • [29] Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
    V Gibaja
    F Shen
    J Harari
    J Korn
    D Ruddy
    V Saenz-Vash
    H Zhai
    T Rejtar
    C G Paris
    Z Yu
    M Lira
    D King
    W Qi
    N Keen
    A Q Hassan
    H M Chan
    Oncogene, 2016, 35 : 558 - 566
  • [30] BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer
    Genta, Sofia
    Pirosa, Maria Cristina
    Stathis, Anastasios
    CURRENT ONCOLOGY REPORTS, 2019, 21 (02)
12345